ReviewKardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery2018
The use of stem cells in ischemic heart disease treatment.
Review in Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Hematopoietic (stem) cells-The elixir of life?FEBS letters · 2026Review
- Human placenta-derived endothelial progenitor cells: an animal-free culture system for efficient expansion.Biological research · 2025Article
- Flow cytometric characterization of cell surface markers to differentiate between fibroblasts and mesenchymal stem cells of different origin.Archives of medical science : AMS · 2023Article
- Hybrid techniques for myocardial regeneration: state of the art and future perspectives.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022Review
- Single-Cell RNA-Seq Identifies Dynamic Cardiac Transition Program from ADCs Induced by Leukemia Inhibitory Factor.Stem cells (Dayton, Ohio) · 2022Article
- Cardiomyocytes induced from hiPSCs by well-defined compounds have therapeutic potential in heart failure by secreting PDGF-BB.Signal transduction and targeted therapy · 2022Article
- A Brief Overview of Global Trends in MSC-Based Cell Therapy.Stem cell reviews and reports · 2022Review
- Early experience with the ThopazKardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2021Article
- Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy.Stem cell research & therapy · 2021Review
- Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives.Frontiers in cell and developmental biology · 2021Review
- MicroRNAs and long noncoding RNAs: new regulators in cell fate determination of mesenchymal stem cells.RSC advances · 2019Review
- Applications of Ultrasound to Stimulate Therapeutic Revascularization.International journal of molecular sciences · 2019Review
- Electrospun nanofibers for the fabrication of engineered vascular grafts.Journal of biological engineering · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.